MedVector is excited to announce the successful closing of a $3,500,000 funding round—a milestone that underscores our mission to transform the clinical trial recruitment landscape. At its core, MedVector is how treating physicians WANT to refer their patients to clinical trials. By simplifying the complexities of clinical trial enrollment, our platform empowers non-investigator physicians to facilitate clinical trial appointments directly from their local practices, eliminating the need to become investigators themselves. This innovative approach not only aligns incentives between treating physicians and investigator teams but also taps into the untapped majority of trial candidates who have traditionally been beyond the reach of conventional research networks.
The new capital will enable MedVector to expand our platform’s capabilities, ensuring that more physicians can seamlessly connect their patients with life-changing clinical trials. Our strategic investments will focus on technology enhancements, user experience improvements, and comprehensive onboard training to educate local practices about the benefits and processes of trial participation. By accelerating enrollment times by years, our mission is to significantly reduce the often lengthy journey from clinical trial discovery to patient access. This funding marks a critical step forward as we continue to break down barriers in clinical research, ultimately paving the way for new and innovative treatments to reach patients faster.
As we embark on this promising new chapter, we remain committed to improving patient outcomes and revolutionizing the clinical trial space. The trust and support shown by our investors serve as a resounding affirmation of the transformative potential MedVector holds in bridging the critical gap between everyday healthcare practices and groundbreaking research.
